Journal: Thrombosis research

Article Title: Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

doi: 10.1016/j.thromres.2011.03.021

Figure Lengend Snippet: Clinical and Laboratory Characteristics of Heparin Treated Patients

Article Snippet: APTT reagent (Triniclot HS, Trinity Biotech, Bray, Ireland) was then added and the reaction was incubated at 37 °C for 3 minutes before initiation of coagulation with CaCl 2 .

Techniques: Biomarker Discovery

Journal: Thrombosis research

Article Title: Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

doi: 10.1016/j.thromres.2011.03.021

Figure Lengend Snippet: A. Concentration dependence of T18R virus-like particle reversal of heparin-prolonged aPTT. B. Concentration dependence of K16M virus-like particle reversal of heparin-prolonged aPTT. C. Percent heparin reversal in patient plasmas. Virus-like particle was added at 180 μg/ml in plasma, T18R (Δ), K16M (○).

Article Snippet: APTT reagent (Triniclot HS, Trinity Biotech, Bray, Ireland) was then added and the reaction was incubated at 37 °C for 3 minutes before initiation of coagulation with CaCl 2 .

Techniques: Concentration Assay, Virus, Clinical Proteomics

Journal: Thrombosis research

Article Title: Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients

doi: 10.1016/j.thromres.2011.03.021

Figure Lengend Snippet: aPTT of plasma are presented after incubation with varying concentrations of protamine or T18R VLP. Plasma samples were collected from six patients before (control without heparin) and during (every 30 minutes) the coronary procedure. A. Protamine correction of aPTT prolongation of individual patient samples. B. T18R VLP correction of aPTT prolongation of individual patient samples. C. Average correction of aPTT prolongation of patient samples, protamine (■), n=14, T18R VLP (▲), n=12. Error bars = SD. D. aPTT of control patient samples without heparin, protamine (■), T18R VLP (▲). A reference aPTT value (47.2 sec) that is the average aPTT value for control patient plasmas without added heparin or VLP is indicated as a ● at X = 0 in panels A, B and C.

Article Snippet: APTT reagent (Triniclot HS, Trinity Biotech, Bray, Ireland) was then added and the reaction was incubated at 37 °C for 3 minutes before initiation of coagulation with CaCl 2 .

Techniques: Clinical Proteomics, Incubation, Control

Journal: Pathophysiology of Haemostasis and Thrombosis

Article Title: Factor V Is an Anticoagulant Cofactor for Activated Protein C during Inactivation of Factor Va

doi: 10.1159/000315141

Figure Lengend Snippet: Control experiments for FVIII sensitivity of the dilute prothrombin time clotting assay. a Pooled normal human plasma was incubated in the absence or presence of 1 μg/ml BO2C11 for 2 h at 37°C and then used in the APTT assay and dilute prothrombin time clotting assay. n = 4. Error bars represent the SEM. b FV-deficient plasma was incubated in the absence (▴, ▵) or presence (•, ○) of 20 μg/ml BO2C11 for 80 min at 37°C and then used in FV titrations, in the absence (▵, ○) or presence (▴, •) of APC. Inset: APCsr. Final concentration of BO2C11 was 1.3 μg/ml. n = 1. c M662C/D1828C-FVIII was titrated in FVIII-deficient plasma and clotting time was measured in the absence (⋄) or presence (♦) of APC. n = 1. d M662C/D1828C-FVIII was titrated in FV-deficient plasma and clotting time was measured in the absence (⋄) or presence (♦) of APC. The FVIII concentration for each data point represents total FVIII present in the final reaction, which included added FVIII plus 0.067 U/ml FVIII present in 15-fold diluted FV-deficient plasma. n = 1.

Article Snippet: Platelin LS activated partial thromboplastin time (APTT) reagent was from Trinity Biotech LPC (Bray, Wicklow, Ireland).

Techniques: Control, Coagulation, Clinical Proteomics, Incubation, Concentration Assay